Results 91 to 100 of about 35,440 (172)

Targeting METTL3 Attenuates Thyroid Inflammatory Injury by Restoring Th17/Treg Balance through a YTHDC2‐m6A‐Dependent KDR/VEGFA Loop

Advanced Science, Volume 13, Issue 45, 13 August 2026.
METTL3‐mediated m6A modification stabilizes KDR/Kdr mRNA through YTHDC2, amplifying the VEGFA‐KDR feedback loop and disturbing Th17/Treg balance. This pathway promotes persistent inflammation and tissue damage in patients with AIT, and inhibiting the METTL3‐KDR axis effectively disrupts this circuit, alleviating thyroid tissue injury and disease ...
Qingyi Hu, Huan Liu, Anwen Ren, Zimei Tang, Jie Tan, Wen Yang, Jie Ming, Tao Huang   +7 more
wiley   +1 more source

Discovery of VEGFR‐2 Inhibitors From Leonurus japonicus via Integrated Genetic Authentication, Molecular Networking, and In Silico Analysis

Archiv der Pharmazie, Volume 359, Issue 8, August 2026.
Genetic authentication of Leonurus japonicus was confirmed using ITS sequencing. UHPLC‐MS/MS‐GNPS analysis and isolation led to a new labdane diterpenoid (1) and known compounds (2–6), with anti‐angiogenic activity validated by EPC assays and VEGFR‐2 docking studies.
Thiyagarajan Raviraj, Chen‐Lin Yu, Aekkhaluck Intharuksa, Shang‐Chih Lai, Vidya Febrasca Tenderly, Yen Chi Loo, Pin‐Wei Chen, Shih‐Wei Wang, Kartiko Arif Purnomo, Soundar Rajan Kulandhaivel, Sedin Renadi, Stephen Lirio, Yuan‐Bin Cheng, Yu‐Liang Yang, Tsong‐Long Hwang, Fang‐Rong Chang, Michal Korinek   +16 more
wiley   +1 more source

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib

Frontiers in Pharmacology
BackgroundSunitinib is approved for the treatment of metastatic renal cell carcinoma (mRCC), imatinib-resistant gastrointestinal stromal tumors (GIST), and advanced pancreatic neuroendocrine tumors (PNET).
Xusheng Zhang, Xiuli Ren, Tianyu Zhu, Wanjin Zheng, Wanjin Zheng, Chengwu Shen, Cuicui Lu   +6 more
doaj   +1 more source

Predicting Poor Efficacy of Cabozantinib in Advanced Renal Cell Carcinoma by Exploratory Metabolic Pathway Analysis and In Vitro Verification

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background Cabozantinib (CABO) is currently an essential drug for first‐line and sequential therapy in the treatment of advanced renal cell carcinoma (RCC). Predicting its therapeutic efficacy will enable efficient drug selection and improve the prognosis of patients.
Takanari Sakai, Yoshihide Kawasaki, Izumi Sakamoto, Eiji Hishinuma, Naomi Matsukawa, Daigo Chiba, Tomonori Sato, Kento Morozumi, Masamitsu Maekawa, Nariyasu Mano, Akihiro Ito   +10 more
wiley   +1 more source

The Local Effects of Systemic Therapies in Urological Oncology: A Systematic Review

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background Systemic therapies can impact local disease progression in genitourinary malignancies, potentially reducing the necessity for extensive surgery. Understanding these effects is crucial for optimizing treatment approaches in urologic oncology.
Sharon Nordheimer, Ofer N. Gofrit
wiley   +1 more source

Harnessing Repurposed Drugs to Enhance Temozolomide Efficacy in Glioblastoma

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Glioblastoma (GB) is the most aggressive primary malignant brain tumor in adults and remains associated with poor survival despite surgical resection followed by radiotherapy and temozolomide (TMZ) chemotherapy. Intrinsic and acquired resistance to TMZ, including MGMT‐dependent DNA repair and activation of pro‐survival pathways ...
Ali Nakhaei, Atefeh Taghavi, Amir R. Afshari, Farzaneh Davoudi, Elaheh Gheybi, Mohammad Jalili‐Nik   +5 more
wiley   +1 more source

Interferon‐induced transmembrane (IFITM) proteins at the tumour–immune interface: A four‐axis framework for their context‐dependent roles

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
Interferon‐induced transmembrane (IFITM) function in cancer is set by four contextual coordinates, not by family membership. Acute interferon input drives major histocompatibility complex class I (MHC‐I)‐linked immunogenicity; chronic input drives programmed death‐ligand 1 (PD‐L1)‐coupled resistance.
Zhe Liu, Jie Meng, Zengyan Lai, Fuqiu Li, Sha Lv   +4 more
wiley   +1 more source

Urokinase Plasminogen Activator Receptor‐Associated Protein (uPARAP) as a Potential Next Generation Molecular Target for Treatment of Gastrointestinal Stromal Tumors (GIST)

International Journal of Cancer, Volume 159, Issue 3, Page 797-808, 1 August 2026.
A key component of the collagen internalization and lysosomal degradation cellular machinery, uPARAP may contribute to cancer progression. Here, the authors explored the expression of uPARAP in gastrointestinal stromal tumors using well‐annotated clinical patient samples and specimens from cell line‐ and patient‐derived xenografts.
Chao‐Chi Wang, Flavia Paternostro, Agnieszka Wozniak, Lore De Cock, Luna De Sutter, Kimberly Verbeeck, Ulla Vanleeuw, Daniël Gorgels, Che‐Jui Lee, Raf Sciot, Patrick Schöffski   +10 more
wiley   +1 more source

Downstream Pathways of Dystrophin Deficiency in Duchenne Muscular Dystrophy: Implications for Muscle Degeneration and Regeneration

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 4, August 2026.
ABSTRACT Background Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrophy, primarily affecting skeletal muscle and leading to premature death. Although the loss of dystrophin has long been recognised as the primary cause of the disease, no definitive cure is currently available. As a consequence, therapeutic efforts
Raffaele Epis, Gabriele Rovetta, Giulia Ferrari, Chiara Bonfanti, Giorgia Careccia, Graziella Messina   +5 more
wiley   +1 more source

SIRT Family: Biological Functions and Therapeutic Targets

MedComm, Volume 7, Issue 8, August 2026.
SIRT1–SIRT7 networks from transgenic mice to human‑relevant therapeutic targets. SIRT1–SIRT7 form an isoform‑, organ‑, and disease‑specific regulatory network. Transgenic Sirt1–7 mouse models define central regulatory SIRTs (SIRT1, SIRT3, SIRT6), context‑dependent modifiers (SIRT2, SIRT4, SIRT5, SIRT7), and their key mechanisms and target organs. These
Jia‐Yi Wang, Feng‐Li Jiang, Fang‐Yuan Zhang, Dong‐Hui Huang, Xiao‐Ying Li, Song Gao, Hua You, Qi‐Jun Wu, Huan‐Huan Chen, Ting‐Ting Gong   +9 more
wiley   +1 more source